160 results
Page 3 of 8
8-K
EX-99.1
jl8f994
28 Jul 22
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
7:06am
DEFA14A
EX-99.1
muh5005x3zysw
11 May 22
Additional proxy soliciting materials
7:08am
8-K
EX-99.1
js9nm
11 May 22
Trevena Reports First Quarter 2022 Results and Provides
7:05am
8-K
EX-99.1
yhk ffc2fir0ocuz48yr
20 Apr 22
Regulation FD Disclosure
5:11pm
8-K
EX-99.1
sffpb0 5y0k3b3r
20 Apr 22
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
8:59am
8-K
EX-99.1
wnwau
31 Mar 22
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing
7:05am
8-K
EX-99.1
glg dy4cte2lyada
31 Mar 22
Trevena Reports Fourth Quarter and Full Year 2021 Results
7:04am
8-K
EX-99.2
kirp5t78l or1
31 Mar 22
Trevena Reports Fourth Quarter and Full Year 2021 Results
7:04am
8-K
EX-99.1
j4zeweetw vdmybhb
27 Jan 22
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical
9:04am
8-K
EX-99.1
p5b6fc
15 Nov 21
Trevena Reports Third Quarter 2021 Results
9:24pm
8-K
EX-99.1
7vwcy
12 Aug 21
Trevena Reports Second Quarter 2021 Results
8:02am
DEFA14A
kbtbrg3a
23 Jul 21
Additional proxy soliciting materials
7:05am
8-K
EX-99.1
1g9ro42 pln
16 Jun 21
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
c2db2cy ww
6 May 21
Trevena Reports First Quarter 2021 Results
7:05am
8-K
EX-99.2
ugtjk03344
6 May 21
Trevena Reports First Quarter 2021 Results
7:05am